Stock Analiz

Eupraxia Pharmaceuticals Inc. EPRX

Pharmaceuticals and Biotechnology · data as of November 13, 2026

$8.15Market cap $537M
Open the interactive analysis →

Eupraxia Pharmaceuticals Inc. (EPRX) is a healthcare company listed in the US with a market value of about $537M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals is listed in the US and classified in pharmaceuticals and biotechnology. It was profitable in 0 of the last 4 years in our data.

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B4.1
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-5.3%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)—
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 4 years

Fiscal year2025202420232022
Revenue$0$0$0—
Net income-$39M-$26M-$28M-$18M
Free cash flow-$29M-$30M-$21M-$14M
EPS (diluted)$-0.59$-0.39$-0.43$-0.28
Net margin————
ROIC————

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 12 analysts is $16.71, 105% above the current price; targets range from $14.00 to $25.00; the consensus rating is “Strong buy”; expected EPS is $-0.96 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Eupraxia Pharmaceuticals pay a dividend?

Not currently.

Is Eupraxia Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Eupraxia Pharmaceuticals scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.